Why Is Rapamycin Not a Rapalog?

Ajla Hodzic Kuerec, Andrea B. Maier*

*Corresponding author for this work

Research output: Contribution to JournalReview articleAcademicpeer-review

Abstract

Rapamycin (sirolimus) is an immunosuppressive drug approved by the Food and Drug Administration (FDA). It is also a leading candidate for targeting aging. Rapamycin and its analogs (everolimus, temsirolimus, ridaforolimus) inhibit the mammalian target of rapamycin (mTOR) kinase by binding to FK506-binding proteins (FKBP) and have a similar chemical structure that only differs in the functional group present at carbon-40. Analogs of rapamycin were developed to improve its pharmacological properties, such as low oral bioavailability and a long half-life. The analogs of rapamycin are referred to as "rapalogs."Rapamycin is the parent compound and should therewith not be called a "rapalog."

Original languageEnglish
Pages (from-to)657-659
Number of pages3
JournalGerontology
Volume69
Issue number6
Early online date6 Jun 2023
DOIs
Publication statusPublished - Jun 2023

Bibliographical note

Funding Information:
This article was funded by an unrestricted grant by the National University of Singapore and the Lien Foundation without any involvement in any parts of the work.

Publisher Copyright:
© 2023 Authors. All rights reserved.

Keywords

  • Aging
  • Mammalian target of rapamycin inhibitors
  • Sirolimus

Fingerprint

Dive into the research topics of 'Why Is Rapamycin Not a Rapalog?'. Together they form a unique fingerprint.

Cite this